Lilly to build manufacturing capacity at risk to prepare for next-gen oral obesity drug
Eli Lilly is stuck in a hard place — it’s got the capital to spend to boost manufacturing capacity. But the complexity of building, buying and getting facilities up and running is a slow process that takes time and technical expertise.
The drugmaker has struggled to produce enough of its GLP-1/GIP agonists even as they generate billions of dollars in sales. Three doses of Mounjaro, the tirzepatide injection approved to treat type 2 diabetes, are now in short supply. And Zepbound, the version of the drug approved to treat patients who are overweight or obese, generated $175 million in sales in less than a month in the US.